Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.

Hanna WM, Slodkowska E, Lu FI, Nafisi H, Nofech-Mozes S.

J Clin Oncol. 2017 Sep 10;35(26):3039-3045. doi: 10.1200/JCO.2016.70.5319. Epub 2017 Apr 26.

PMID:
28445098
2.

Myoid Hamartoma of the Breast with Symplastic Changes.

Felipe Lima J, Sirkin W, Hanna WM.

Breast J. 2016 Sep;22(5):583-4. doi: 10.1111/tbj.12642. Epub 2016 Jun 27. No abstract available.

PMID:
27346672
3.

Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.

Hanna WM, Barnes PJ, Chang MC, Gilks CB, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S.

J Clin Oncol. 2014 Dec 10;32(35):3967-73. doi: 10.1200/JCO.2014.55.6092. Epub 2014 Nov 10.

PMID:
25385731
4.

Oxidant-antioxidant status in Egyptian children with sickle cell anemia: a single center based study.

El-Ghamrawy MK, Hanna WM, Abdel-Salam A, El-Sonbaty MM, Youness ER, Adel A.

J Pediatr (Rio J). 2014 May-Jun;90(3):286-92. doi: 10.1016/j.jped.2013.09.005. Epub 2014 Feb 5.

5.

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.

Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G.

Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Review.

6.

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status.

Penault-Llorca F, Coudry RA, Hanna WM, Osamura RY, Rüschoff J, Viale G.

Breast. 2013 Apr;22(2):200-2. doi: 10.1016/j.breast.2012.12.004. Epub 2013 Jan 24.

PMID:
23352656
7.

Lymphoepithelioma-like carcinoma of the breast: a diagnostic and therapeutic challenge.

Dinniwell R, Hanna WM, Mashhour M, Saad RS, Czarnota GJ.

Curr Oncol. 2012 Jun;19(3):e177-83. doi: 10.3747/co.19.926.

8.

Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.

Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hanna WM.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):684-96. doi: 10.1016/j.clon.2012.04.005. Epub 2012 May 18.

PMID:
22608362
9.

Systematic review on hormone receptor testing in breast cancer.

Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hagerty KL, Mangu PB, Temin S, Hanna WM.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):214-63. doi: 10.1097/PAI.0b013e318234aa12. Review.

PMID:
22505008
10.

Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.

Cancer. 2009 Nov 1;115(21):4917-23. doi: 10.1002/cncr.24573.

11.

Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.

Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M.

J Clin Oncol. 2009 Apr 1;27(10):1694-705. doi: 10.1200/JCO.2008.17.3989. Epub 2009 Mar 2. Review.

PMID:
19255333
12.

Intraoperative consultation for axillary sentinel lymph node biopsy: an 8-year audit.

Nofech-Mozes S, Hanna WM, Cil T, Quan ML, Holloway C, Khalifa MA.

Int J Surg Pathol. 2010 Apr;18(2):129-37. doi: 10.1177/1066896909332114. Epub 2009 Feb 17.

PMID:
19223378
13.

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.

Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM.

Breast Cancer Res Treat. 2009 Nov;118(1):131-7. doi: 10.1007/s10549-008-0295-8. Epub 2009 Feb 3.

PMID:
19189211
14.

Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Hanna WM, Hammond E, Taylor CR, Dabbs DJ, Penault-Llorca F, Bloom KJ, Bilous M, Badve S.

Mod Pathol. 2008 Oct;21(10):1278-80; author reply 1280-1. doi: 10.1038/modpathol.2008.131. No abstract available.

15.

Immunophenotyping of serous carcinoma of the female genital tract.

Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, Ghorab Z.

Mod Pathol. 2008 Sep;21(9):1147-55. doi: 10.1038/modpathol.2008.108. Epub 2008 Jun 20.

16.

Pattern of metastatic spread in triple-negative breast cancer.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.

Breast Cancer Res Treat. 2009 May;115(2):423-8. doi: 10.1007/s10549-008-0086-2. Epub 2008 Jun 10.

PMID:
18543098
17.

Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.

Djordjevic B, Hanna WM.

Mod Pathol. 2008 Oct;21(10):1238-45. doi: 10.1038/modpathol.2008.78. Epub 2008 May 23.

18.

Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls.

Woolcott CG, SenGupta SK, Hanna WM, Aronson KJ.

BMC Cancer. 2008 May 8;8:130. doi: 10.1186/1471-2407-8-130.

19.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

20.

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ.

Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30.

21.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists.

Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.

PMID:
19548375
22.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189
23.

Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.

Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A.

Breast J. 2006 Jul-Aug;12(4):294-301.

PMID:
16848838
25.

Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.

Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI.

Breast J. 2006 Jan-Feb;12(1):37-47.

PMID:
16409585
26.

A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer.

Burger AM, Gao Y, Amemiya Y, Kahn HJ, Kitching R, Yang Y, Sun P, Narod SA, Hanna WM, Seth AK.

Cancer Res. 2005 Nov 15;65(22):10401-12.

27.

Prognostic factors affecting the natural history of node-negative breast cancer.

Trudeau ME, Pritchard KI, Chapman JA, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, Andrulis I, McCready DR, Lickley HL.

Breast Cancer Res Treat. 2005 Jan;89(1):35-45.

PMID:
15666195
28.

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.

Clin Cancer Res. 2004 Mar 15;10(6):2029-34.

29.

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL.

J Clin Oncol. 2004 Jan 1;22(1):86-96.

PMID:
14701769
30.

In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma.

Miller NA, Chapman JA, Fish EB, Link MA, Fishell E, Wright B, Lickley HL, McCready DR, Hanna WM.

Breast J. 2001 Sep-Oct;7(5):292-302.

PMID:
11906438
31.

Organochlorines and breast cancer risk by receptor status, tumor size, and grade (Canada).

Woolcott CG, Aronson KJ, Hanna WM, SenGupta SK, McCready DR, Sterns EE, Miller AB.

Cancer Causes Control. 2001 Jun;12(5):395-404.

PMID:
11545454
32.

Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.

Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A.

Mod Pathol. 2001 Jul;14(7):677-85.

33.

Pathologic Characteristics of Breast Cancer that Predict for Local Recurrence After Lumpectomy Alone.

Hanna WM, Kahn HJ, Chapman JA, Fish EB, Lickley HL, McCready DR.

Breast J. 1999 Mar;5(2):105-111.

PMID:
11348268
34.

Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients.

McCready DR, Chapman JA, Hanna WM, Kahn HJ, Yap K, Fish EB, Lickley HL.

Ann Surg Oncol. 2000 Sep;7(8):562-7.

PMID:
11005553
35.

The prevalence of delta virus infection in chronic liver disease in Egyptian children in comparison with some other countries.

Morcos MM, Mikhail TH, Hanna WM, Abdel-Fattah S, el-Rasad MM, Wassef EL.

Panminerva Med. 2000 Jun;42(2):97-100.

PMID:
10965769
36.

Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model.

McCready DR, Chapman JA, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley HL.

Ann Surg Oncol. 2000 Jul;7(6):416-26. Review.

PMID:
10894137
37.

Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk.

Aronson KJ, Miller AB, Woolcott CG, Sterns EE, McCready DR, Lickley LA, Fish EB, Hiraki GY, Holloway C, Ross T, Hanna WM, SenGupta SK, Weber JP.

Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):55-63.

38.

Cardiac valvular papillary fibroelastoma: a report of 2 cases.

Madhu Sankar N, Odayan MK, Morris M, Paterson H, Hanna WM.

Tex Heart Inst J. 1999;26(4):298-9.

39.

Granuloma annulare: an elastic tissue disease? Case report and literature review.

Hanna WM, Moreno-Merlo F, Andrighetti L.

Ultrastruct Pathol. 1999 Jan-Feb;23(1):33-8. Review.

PMID:
10086915
40.

Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.

Fish EB, Chapman JA, Miller NA, Link MA, Fishell E, Wright B, McCready DR, Hiraki GY, Ross TM, Hanna WM, Lickley HL.

Ann Surg Oncol. 1998 Dec;5(8):724-32.

PMID:
9869520
41.

Symptomatic lipoma in the right atrial free wall. A case report.

Sankar NM, Thiruchelvam T, Thirunavukkaarasu K, Pang K, Hanna WM.

Tex Heart Inst J. 1998;25(2):152-4.

42.

Kindler syndrome. Clinical and ultrastructural findings.

Haber RM, Hanna WM.

Arch Dermatol. 1996 Dec;132(12):1487-90.

PMID:
8961879
43.

The Henrietta Banting Breast Centre database: a model for clinical research utilizing a hospital-based inception cohort.

Sawka CA, Pritchard KI, Lickley HL, Oldfield GA, Chapman JA, Allen GG, Mobbs BG, Hanna WM, Kahn H, Trudeau ME, et al.

J Clin Epidemiol. 1995 Jun;48(6):779-86.

PMID:
7769408
44.

"Aberrant elastic" in elastofibroma: an immunohistochemical and ultrastructural study.

Kahn HJ, Hanna WM.

Ultrastruct Pathol. 1995 Jan-Feb;19(1):45-50.

PMID:
7770961
45.

Epidermolysis bullosa acquisita with features of bullous lupus erythematosus.

Prussick R, Gupta AK, Assaad DM, Hanna WM, Sauder DN.

Int J Dermatol. 1994 Mar;33(3):192-5. No abstract available.

PMID:
8169020
46.

The standardization of estrogen receptors.

Chapman JA, Mobbs BG, Hanna WM, Sawka CA, Pritchard KI, Lickley HL, Trudeau ME, Ryan ED, Ooi TC, Sutherland DJ, et al.

J Steroid Biochem Mol Biol. 1993 May;45(5):367-73.

PMID:
7684604
47.

Subcellular localization of HMFG2 in breast carcinomas: an immunohistochemical and immunoelectron microscopic study.

Hanna WM, Kahn HJ, Zive SE, Shackleton M, Andrighetti L.

Mod Pathol. 1992 Nov;5(6):603-6.

PMID:
1369793
48.

The correlation of Ki67 growth factor and ERICA in breast cancer.

Hanna WM, Kahn HJ, Chapman JA.

Mod Pathol. 1992 May;5(3):220-3.

PMID:
1495928
49.

A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer.

Chapman JA, Trudeau ME, Pritchard KI, Sawka CA, Mobbs BG, Hanna WM, Kahn H, McCready DR, Lickley LA.

Breast Cancer Res Treat. 1992;22(3):263-72.

PMID:
1391992
50.

Myotomy for reflux-induced cricopharyngeal dysphagia. Five-year review.

Henderson RD, Hanna WM, Henderson RF, Marryatt G.

J Thorac Cardiovasc Surg. 1989 Sep;98(3):428-33.

PMID:
2770324

Supplemental Content

Loading ...
Support Center